Renaissance Capital logo

Biotech IPOs Focused on NASH

March 4, 2019

After years of disappointing clinical trials for nonalcoholic steatohepatitis (NASH), an often fatal liver disease associated with obesity and diabetes, there are a number of promising late-stage clinical trials underway, including two being conducted by pending biotech IPOs Cirius Therapeutics (CSTX) and Genfit (GNFT). NASH affects 20 million people with no FDA-approved therapies and is a multi-billion dollar opportunity.

Cirius recently reported positive interim results in a Phase 2 trial for its once daily oral small molecule that is a selective modulator of mitochondrial metabolism. It has enrolled a Phase 2b trial that will be the basis for designing a larger pivotal trial...

To read the entire article, sign up for a free 7-day trial of IPO Pro, the single, most effective IPO data platform you'll ever need.
Start a Free Trial of IPO Pro